Comparing further treatment options for esophageal cancer after chemo-immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years
- Diagnosed with locally advanced esophageal cancer that can be surgically removed
- Must have had at least 2 cycles of platinum-based chemo plus an immunotherapy drug (like anti-PD-1) and the cancer has either completely or partially responded
- Good overall health with a performance status of 0 or 1 (able to carry out daily activities)
- Adequate organ function (kidney, liver, bone marrow) as confirmed by blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial looks at how best to add an immunotherapy “extra” before, during, and after standard chemoradiation for stage II–III esophageal squamous cell cancer that can’t be operated on. It may help reduce cancer that remains after treatment by targeting immune cells.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.